Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose DG3173 vs Octreotide in Untreated Acromegaly
NCT02235987Phase 2Completed
- Sponsor
- Aspireo Pharmaceuticals Ltd.
- Start
- Oct 2012
- Primary completion
- Dec 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of veldoreotide in acromegaly, sponsored by Aspireo Pharmaceuticals Ltd. Primary endpoint: Participants With Trough Human Growth Hormone < 2.5 ug/mL at 8 hours. Started Oct 2012; status: completed.
02
Drugs
veldoreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT02235987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235987.